

HHS Public Access

J Pain Symptom Manage. Author manuscript; available in PMC 2019 July 26.

Published in final edited form as:

Author manuscript

J Pain Symptom Manage. 2018 August ; 56(2): e4-e8. doi:10.1016/j.jpainsymman.2018.05.001.

Quality of Life, Symptoms, and Self-Management Strategies After Gastroesophageal Cancer Surgery

Oliver S. Eng, MD¹, Jae Y. Kim, MD², Nora Ruel, MA³, Dan J. Raz, MD², Loretta Erhunmwunsee, MD², Laleh G. Melstrom, MD¹, Joseph Chao, MD⁴, Yanghee Woo, MD¹, Joseph Kim, MD⁵, Virginia Sun, PhD, RN⁶

¹Division of Surgical Oncology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA

²Division of Thoracic Surgery, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA

³Biostatistics Core, Department of Information Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA

⁴Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA

⁵Department of Surgery, SUNY Stony Brook, Stony Brook, NY

⁶Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA

Keywords

Esophageal cancer; gastric cancer; quality of life; symptoms; dietary adjustments; self-management

To the Editor:

The most common and effective treatment strategy for gastroesophageal cancer is surgery. Surgical procedures (esophagectomy, gastrectomy) are invasive and complex, and risk for postoperative complications is high (up to 40%).¹ Postoperative recovery is slow, with impairments in quality of life (QOL) that can persist ten years after surgery.² Nutritional symptoms are common (nausea, vomiting, early satiety, diarrhea, pain), and often result in severe malnutrition.³ These symptoms and associated eating problems are often a major source of anxiety for patients postoperatively.⁴ Few studies have attempted to understand the strategies that gastroesophageal cancer patients use to manage nutritional symptoms and eating problems. In this study, we evaluated QOL, symptoms, and self-management strategies following gastroesophageal cancer surgery.

Correspondence: Oliver S. Eng, MD, Division of Surgical Oncology, Department of Surgery, City of Hope, 1500 East Duarte Road, Duarte, California, 91010, USA; Ph: 626-218-7100; Fax: 626-218-6865; oeng@coh.org.

Dr. Joseph Kim, Dr. Jae Kim, and Dr. Sun contributed equally to the conception and design of the study.

Presented at the ASCO GI Cancers Symposium, January 19-21, 2017, San Francisco, CA

Conflict of Interest Statement: All authors have no disclosures to report.

Methods

This cross-sectional study was conducted at an NCI-designated comprehensive cancer center and approved by the Institutional Review Board (IRB). Using existing institutional surgery datasets from 2014 to 2015, we identified eligible participants using the following criteria: 1) had an esophagectomy or gastrectomy, 2) were 6–12 months post-resection, and 3) were 21 years of age and older. A packet containing an invitation letter for study participants and informed consent was mailed to eligible participants. Research staff contacted participants one week after packet mailing. Following informed consent, surveys were completed verbally or by postage-paid mailing based on patient preference.

All participants completed the following validated measures: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ30), the EORTC-Oesophageal or Gastric Cancer Module (EORTC-QLQ-OES18 or STO22), and dietary patterns and behavioral adjustments questions from the City of Hope-Quality of Life tool (COH-QOL). The EORTC-QLQ is a well-validated 30-item instrument for QOL assessment, with subscales/items for function, global health, general symptoms (fatigue, pain, nausea & vomiting), and financial toxicity.⁵ The EORTC-QLQ-OES18 is an 18-item measure of esophageal cancer-specific symptoms and emotional sequelae.⁶ The EORTC-QLQ-STO22 is a 22-item measure for gastric cancer-specific symptoms and emotional-wellbeing.⁷ Finally, we used questions from the validated 43-item COH-OOL tool to assess diet and behavioral adjustments. These included time to comfort with diet, number of meals/ snacks/drinks per day, and number/types of behavioral/lifestyle adjustments to control symptoms and enhance nutritional intake.⁸ Descriptive statistics (means for normallydistributed continuous data, medians for non-normally distributed continuous data, and proportions for categorical data) were summarized for sociodemographics, clinical, disease, QOL, symptoms, and self-management data.

Results

The overall response rate to the survey was 67% (31 complete/46 eligible), with 11 esophagectomy and 20 gastrectomy participants enrolled. Mean age was 62 (range 42–87), and most participants were male (64.5%). Disease stage distribution are as follows: 11 stage I (35.5%), 2 stage II (6.4%), 15 stage III (48.4%), and 3 stage IV gastric cancer patients (9.7%). Fourteen participants (45.2%) received neoadjuvant chemotherapy/chemoradiation (ECF, carboplatin/paclitaxel), and 16 (51.6%) were treated adjuvantly (FOLFOX, radiation). Most participants (26; 83.8%) reported having 2 or more preoperative comorbidities. Thirty-day postoperative complication rate was 35.4%; 5 participants (16.1%) were readmitted at 90 days after surgery.

QOL and symptom scores (general and disease-specific) are presented in Table 1. Global health status scores were moderate (62.9 ± 12.0 esophagectomy, 64.6 ± 23.9 gastrectomy). For QOL subscales, social functioning score was the lowest for esophagectomy patients (62.1 ± 29.9), while role functioning was the lowest for gastrectomy patients (73.3 ± 32.2). For general symptoms, fatigue was the most severe for esophagectomy patients (45.4 ± 23.5), followed by appetite loss, insomnia, and dyspnea. For gastrectomy patients, financial difficulties was the most severe (40.0 ± 44.1), followed by fatigue, appetite loss, and

insomnia. For disease-specific symptoms, eating restrictions was a major problem for all patients. Trouble with cough, taste, and reflux were also problematic for esophagectomy patients. Gastrectomy patients reported problems with body image, dry mouth, and pain.

For diet adjustments, most participants felt comfortable with eating between 1–12 months after surgery, but a subset of participants (5; 16.1%) reported never achieving comfort with eating at the time of survey. Most participants ate an average of 3–4 meals per day (range 2–7), with an average of 2 snacks per day (range 0–5). The number of behavioral and lifestyle changes since surgery ranged from 2 to 9. A variety of behavioral and lifestyle self-management strategies were reported for symptom management. Participants chewed food completely, ate smaller meals throughout the day, and controlled their meal portions to manage symptoms and eating problems. Other reported strategies included staying/sitting upright after eating, keeping upper body/head raised when sleeping, and planning social activities around eating.

Comment

Eating problems and associated symptoms are among the most common complications after gastroesophageal cancer surgery. Importantly, nutritional symptoms and eating problems are modifiable, underscoring the need to identify effective approaches that contribute to symptom relief. Our findings confirm evidence from previous studies, which also found lower social/role functioning and similar persistent symptoms (fatigue, appetite loss) six months after surgery.⁴ Although gastroesophageal cancer surgery primarily impacts symptoms related to eating, this can affect multiple QOL domains. Many normal social interactions center around meals, and not being able to participate fully may have a detrimental impact on QOL. Patients who experience a high nutritional symptom burden and more eating difficulties may experience poor social well-being and challenges with roles and relationships. Further research is needed to understand patients' postoperative social and role functioning needs.

We observed variations in time to comfort with eating after surgery, which happened for most patients around 1–12 months. Importantly, some patients never felt comfortable with eating. In addition, it appears that multiple behavioral and lifestyle self-management strategies were undertaken, but the type of strategy varied tremendously. This may be due to several potential factors, including use of trial-and-error approaches for choice of strategies, a lack of structured guidance and coaching, and inconsistent efficacy that results in variations in choice of strategies. Factors such as age, gender, level of education, treatments before and after surgery, and time since surgery could also potentially explain the variations observed. Currently, many gastroesophageal cancer patients are given post-operative instructions on nutrition. However, not all patients have access to nutritional counseling services. While registered dietitian nutritionists (RDNs) provide the expertise to meet this challenge, evidence shows that even in comprehensive cancer centers RDN services are not readily available. Current patient-to-RDN ratios exceed 1000:1.⁹ Alternative approaches are essential to meet patients' nutritional needs after gastroesophageal cancer surgery.

We had previously postulated that personalized, self-management interventions in the perioperative setting for gastroesophageal cancer should account for patient preferences,

cultural context, and tolerance in dietary patterns.¹⁰ A personalized approach, using classic diet behavior change theories (goal setting, problem-solving, motivational interviewing) may be necessary to help patients adjust successfully to their new diet patterns after surgery. Nutritional symptom characteristics and eating problems are dynamic in frequency and severity, suggesting that effective interventions will need to be flexible in meeting individual needs.

Several limitations of the study warrant further discussion. First, the overall small sample size and single institution design limits the ability to draw conclusions from the findings, and precludes the ability to perform additional meaningful statistical analyses. Second, the cross-sectional design with a single point-in-time assessment may result in recall bias. Third, our findings may be confounded by other variables, such as time since surgery, receipt of adjuvant treatment during survey completion, number of comorbid conditions, and other characteristics. Additional limitations include lack of baseline data (before surgery), lack of comparator, and wide timeframe of assessment (6–12 months post-op). Future studies with a larger sample size using a prospective, longitudinal approach may provide more clinically-relevant information on symptom trajectory and changes in self-management strategies.

In conclusion, patients who have undergone gastroesophageal cancer surgery may experience long-term challenges that can adversely impact their QOL. Many patients adopt their own behavior and lifestyle modifications to manage symptoms. Interventions are needed to support postoperative recovery, adoption of new diet patterns, and symptom management.

Acknowledgments:

The research reported in this paper included work performed by the Survey Research Core and Biostatistics Core that are supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and do not necessarily represent the official views of the NCI or NIH.

References

- Park KU, Rubinfeld I, Hodari A, Hammoud Z. Prolonged length of stay after esophageal resection: identifying drivers of increased length of stay using the NSQIP database. J Am Coll Surg 2016;223(2):286–290. [PubMed: 27118713]
- Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer 2016;69:43–50. [PubMed: 27816831]
- Heneghan HM, Zaborowski A, Fanning M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg 2015;262(5):803–807. [PubMed: 26583669]
- 4. Viklund P, Wengström Y, Rouvelas I, Lindblad M, Lagergren J. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006;42(10):1407–1414. [PubMed: 16737812]
- Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Instit 1993;85(5):365–376.
- 6. Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003;39(10):1384–1394. [PubMed: 12826041]

- Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004;40(15):2260–2268. [PubMed: 15454251]
- Wendel CS, Grant M, Herrinton L, et al. Reliability and validity of a survey to measure bowel function and quality of life in long-term rectal cancer survivors. Qual Life Res 2014;23(10):2831– 2840. [PubMed: 24890826]
- Platek ME, Johnson J, Woolf K, Makarem N, Ompad DC. Availability of outpatient clinical nutrition services for patients with cancer undergoing treatment at comprehensive cancer centers. J Oncol Pract 2015;11(1):1–5. [PubMed: 25185213]
- Sun V, Kim J, Kim JY, et al. Dietary alterations and restrictions following surgery for upper gastrointestinal cancers: Key components of a health-related quality of life intervention. Eur J Oncol Nurs 2015;19(4):343–348. [PubMed: 25697545]

Quality of Life and Symptom Scores

| Quality of Life - mean±SD (range), median (IQR) - EORTC-QLQ30; 0-100; higher = better | | |
|---|---|---|
| Items | Esophageal (N=11) | Gastric (N=20) |
| Global Health Status | 62.9±12.0 (41.7–83.3) 66.7 (50.0–66.7) | 64.6±23.9 (16.7–100.0) 66.7 (50.0–83.3) |
| Physical Functioning | 73.3±18.9 (46.7–93.3) 80.0 (53.3–93.3) | 78.3±22.6 (13.3–100.0) 86.7 (70.0–93.3) |
| Role Functioning | 63.6±33.2 (0.0–100.0) 66.7 (33.3–100.0) | 73.3±32.2 (0.0–100.0) 83.3 (58.3–100.0) |
| Emotional Functioning | 75.0±10.5 (66.7–100.0) 75.0 (66.7–83.3) | 79.2±21.0 (41.7–100.0) 83.3 (62.5–100.0) |
| Cognitive Functioning | 77.3±20.1 (33.3–100.0) 83.3 (66.7–100.0) | 78.3±21.7 (33.3–100.0) 83.3 (66.7–100.0) |
| Social Functioning | 62.1±29.9 (16.7–100.0) 66.7 (33.3–83.3) | 75.0±31.8 (0.0–100.0) 83.3 (66.7–100.0) |
| Fatigue | 45.5±23.5 (11.1–88.9) 33.3 (33.3–66.7) | 30.6±27.2 (0.0–100.0) 27.8 (11.1–55.6) |
| Nausea and vomiting | 22.7±25.0 (0.0–66.7) 16.7 (0.0–50.0) | 12.5±13.1 (0.0–33.3) 16.7 (0.0–16.7) |
| Dyspnea | 27.3±29.1 (0.0–66.7) 33.3 (0.0–66.7) | 15.0±22.9 (0.0–66.7) 0.0 (0.0–33.3) |
| Insomnia | 30.3± 27.7 (0.0–66.7) 33.3 (0.0–66.7) | 18.3±22.9 (0.0–66.7) 0.0 (0.0–33.3) |
| Appetite loss | 33.3±33.3 (0.0–100.0) 33.3 (0.0–66.7) | 26.7±36.8 (0.0–100.0) 0.0 (0.0–66.7) |
| Constipation | 21.2±22.5 (0.0–66.7) 33.3 (0.0–33.3) | 15.0±25.3 (0.0–100.0) 0.0 (0.0–33.3) |
| Diarrhea | 24.2±15.6 (0.0–33.3) 33.3 (0.0–33.3) | 15.0±25.3 (0.0–66.7) 0.0 (0.0–33.3) |
| Financial Difficulties | 27.3±32.7 (0.0–100.0) 33.3 (0.0–33.3) | 40.0±44.1 (0.0–100.0) 33.3 (0.0–100.0) |
| Disease-Specific Symptoms - mean±SD (range), median (IQR) - <i>0–100; higher = worse</i> | | |
| Items | Esophageal (N=11) EORTC-QLQ-OES18 | Gastric (N=20) EORTC-QLQ-STO22 |
| Eating Restrictions | 48.5±23.5 (8.3–91.7) 50.0 (25.0–66.7) | 26.7±21.4 (0.0–75.0) 16.7 (8.3–37.5) |
| Reflux symptoms | 28.8±32.6 (0-100) 16.7 (0.0-50.0) | 17.2±17.8 (0.0–55.6) 11.1 (0.0–27.8) |
| Pain | 20.2± 13.9 (0.0–33.3) 22.2 (11.1–33.3) | 23.8±23.3 (0.0–75.0) 25.0 (0.0–33.3) |
| Trouble swallowing saliva | 27.3±32.7 (0.0–100.0) 33.3 (0.0–33.3) | NA |
| Choked when swallowing | 27.3±32.7 (0.0–100.0) 33.3 (0.0–33.3) | NA |
| Dry mouth | 21.2±27.0 (0.0–66.7) 0.0 (0.0–33.3) | 25.0±32.2 (0.0–100.0) 16.7 (0.0–33.3) |
| Trouble with taste | 39.4±38.9 (0.0–100.0) 33.3 (0.0–66.7) | 20.0±33.2 (0.0–100.0) 0.0 (0.0–33.3) |

| Quality of Life - mean±SD (range), median (IQR) - EORTC-QLQ30; 0–100; higher = better | | |
|---|--|---|
| Items | Esophageal (N=11) | Gastric (N=20) |
| Trouble with coughing | 39.4±38.9 (0.0–100.0) 33.3 (0.0–66.7) | NA |
| Trouble with talking | 21.2±16.8 (0.0–33.3) 33.3 (0.0–33.3) | NA |
| Dysphagia | 21.2±20.2 (0.0–55.6) 11.1 (0.0–44.4) | 10.6±13.2 (0.0–44.4) 11.1 (0.0–11.1) |
| Body Image | NA | 26.7±25.6 (33.3–100.0) 33.3 (0.0–33.3) |

NA=question not included in survey